Poor
Not Aligned
Patient Risk:
Moderate
Summary
Mechanism of action aligns with the provided label (12.1), but most safety-related and adverse reaction specificity claims are not supported by the provided label excerpts (limited 5 and no adverse reaction details).
Category Scores
Accurate Statements
Cosentyx works by targeting and blocking the activity of interleukin-17A (IL-17A).
Supported by 12.1 Mechanism of Action: selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
No treatment/indication statement is present in the provided label sections (12.1; brief 5 list).
Common side effects of Cosentyx include injection site reactions (e.g., redness, swelling, pain).
No such adverse reaction details are present in the provided excerpts.
Common side effects of Cosentyx include upper respiratory tract infections (e.g., bronchitis, pneumonia).
Provided excerpt only references 'Infections' generally; no 'common' URTI/bronchitis/pneumonia details.
Common side effects of Cosentyx include nasopharyngitis.
Nasopharyngitis is not mentioned in the provided excerpts.
Common side effects of Cosentyx include headache.
Headache is not mentioned in the provided excerpts.
Common side effects of Cosentyx include fatigue.
Fatigue is not mentioned in the provided excerpts.
Common side effects of Cosentyx include muscle pain.
Muscle pain is not mentioned in the provided excerpts.
Serious infections associated with Cosentyx include sepsis.
No sepsis mention in the provided excerpts; only 'Infections' category is referenced.
Serious infections associated with Cosentyx include pneumonia.
No pneumonia mention in the provided excerpts.
Serious infections associated with Cosentyx include tuberculosis.
No tuberculosis mention in the provided excerpts.
Allergic reactions with Cosentyx may include anaphylaxis.
No anaphylaxis mention in the provided excerpts.
There have been reports of malignancies, including lymphoma, in patients taking Cosentyx.
No malignancy/lymphoma statements in the provided excerpts.
Cosentyx can trigger or exacerbate autoimmune disorders, such as lupus or rheumatoid arthritis.
No autoimmune disorder triggering/exacerbation statements in the provided excerpts.
Serious skin reactions with Cosentyx can include Stevens-Johnson syndrome.
No SJS mention in the provided excerpts.
Serious skin reactions with Cosentyx can include toxic epidermal necrolysis.
No TEN mention in the provided excerpts.
Cosentyx can exacerbate psoriasis symptoms in some cases.
No statement about worsening psoriasis in the provided excerpts.
Cosentyx can cause or worsen arthritis-related side effects.
No arthritis-related side effects statements in the provided excerpts.
Arthritis-related side effects with Cosentyx can include joint pain and swelling.
No joint pain/swelling or arthritis-related adverse reactions in the provided excerpts.
Some patients may experience eye problems with Cosentyx.
No eye problems mention in the provided excerpts.
Eye problems with Cosentyx can include uveitis.
No uveitis mention in the provided excerpts.
Eye problems with Cosentyx can include conjunctivitis.
No conjunctivitis mention in the provided excerpts.
Contradictions
Important Omissions
FDA-label-aligned indication(s), dosage/administration, contraindications, and detailed warnings/precautions (beyond the brief adverse reaction category references) are not addressed/verified within the provided evaluation scope.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple specific safety assertions (e.g., sepsis/TB/anaphylaxis/malignancy/SJS-TEN/uveitis) are not supported by the provided label excerpts, limiting confidence in label alignment. Mechanism of action is supported, but safety specificity is largely unverified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most adverse reaction and safety claims (including seriousness and specific entities like sepsis/TB/anaphylaxis/SJS-TEN/uveitis) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to those explicitly supported by the provided label sections (12.1 IL-17A mechanism) and remove or qualify safety/adverse reaction specifics that are not present in the supplied excerpts.